1037309-45-7

Basic information

• Product Name: Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt
• Synonyms: Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt;MP 10 succinate salt;PF-2545920 (succinate salt);2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate
• CAS NO: 1037309-45-7
• Molecular Formula: C₄H₆O₄*C₂₅H₂₀N₄O
• Molecular Weight: 510.54054
• Mol File: 1037309-45-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt(1037309-45-7)
• EPA Substance Registry System: Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt(1037309-45-7)

Safety Data

• Hazardous Substances Data: 1037309-45-7(Hazardous Substances Data)

Usage

General Description

Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]-, succinate salt is a chemical compound that consists of a quinoline core with a succinate salt. It contains a complex structure with a quinoline ring, a phenoxy methyl group, and a pyrazol-3-yl group. The succinate salt form of the compound makes it more stable and easier to handle. This chemical may have potential applications in pharmaceuticals, research, and chemical industries due to its unique structure and properties. It is important to handle this compound with care and follow proper safety protocols when working with it.

Upstream product

• 898562-94-2 2-({4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline 
• 110-15-6 succinic acid 

Relevant articles and documents

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.